Once-weekly carfilzomib appears to be more effective than the standard twice-weekly regimen for patients with relapsed or refractory multiple myeloma. The findings from the ARROW study, presented at ASCO 2018 and published concurrently in The Lancet Oncology, support a change to a more convenient, sustainable dosing schedule for patients. The open label, phase 3 trial ...
Switch to once-weekly carfilzomib looks promising in multiple myeloma
By Mardi Chapman
13 Jun 2018